# A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

> **NCT06635772** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 90 (estimated)

## Conditions studied

- Immunoglobulin a Nephropathy

## Interventions

- **DRUG:** HS-10390
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT06635772
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06635772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06635772, "A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06635772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*